A maturation model for midazolam clearance

Paediatric Anaesthesia

Volumn 21, Issue 3, 2011, Pages 302-308

  Anderson, Brian J ^a   Larsson, Peter ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

allometrics; children; maturation; midazolam; pharmacokinetics

Indexed keywords

MIDAZOLAM;

ADOLESCENT; ADULTHOOD; ANESTHESIA LEVEL; ARTICLE; CHILD; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; HUMAN; INFANT; MENSTRUAL CYCLE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; AGING; ALGORITHMS; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; FEMALE; HALF-LIFE; HUMANS; HYPNOTICS AND SEDATIVES; INFANT; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MIDAZOLAM; MODELS, STATISTICAL; NONLINEAR DYNAMICS; PREGNANCY;

EID: 78650500434     PISSN: 11555645     EISSN: 14609592     Source Type: Journal    
DOI: 10.1111/j.1460-9592.2010.03364.x     Document Type: Article

References (68)

1. Tod M, Jullien V, Pons G,. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet 2008; 47: 231-243. (Pubitemid 351367434)
2. Anderson BJ, Allegaert K, Holford NHG,. Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr 2006; 165: 819-829. (Pubitemid 44627767)
3. Waisel DB,. Moral responsibility to attain thorough pediatric drug labeling. Paediatr Anaesth 2009; 19: 989-993.
4. Johnson TN,. The problems in scaling adult drug doses to children. Arch Dis Child 2008; 93: 207-211. (Pubitemid 352025489)
5. Johnson TN, Rostami-Hodjegan A, Tucker GT,. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 2006; 45: 931-956. (Pubitemid 44299829)
6. Edginton AN, Schmitt W, Voith B, et al. A mechanistic approach for the scaling of clearance in children. Clin Pharmacokinet 2006; 45: 683-704. (Pubitemid 43990570)
7. Anderson BJ, Holford NH,. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303-332. (Pubitemid 351738156)
8. Anderson BJ, Holford NH,. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 2009; 24: 25-36.
9. West GB, Brown JH,. The origin of allometric scaling laws in biology from genomes to ecosystems: towards a quantitative unifying theory of biological structure and organization. J Exp Biol 2005; 208: 1575-1592. (Pubitemid 40697606)
10. Anderson BJ, Meakin GH,. Scaling for size: some implications for paediatric anaesthesia dosing. Paediatr Anaesth 2002; 12: 205-219. (Pubitemid 34264439)
11. Hill AV,. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J Physiol 1910; 14: iv-vii.
12. Reed MD, Rodarte A, Blumer JL, et al. The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration. J Clin Pharmacol 2001; 41: 1359-1369. (Pubitemid 33104904)
13. Anderson BJ, Hansen TG,. Getting the best from pediatric pharmacokinetic data. Paediatr Anaesth 2004; 14: 713-715. (Pubitemid 39223081)
14. Engle WA,. Age terminology during the perinatal period. Pediatrics 2004; 114: 1362-1364. (Pubitemid 41647702)
15. Beal SL, Boeckmann AJ, Sheiner LB,. NONMEM Project Group. NONMEM Users Guides. San Francisco: University of California, 1999.
16. Peck CC, Sheiner LB, Nichols AI,. The problem of choosing weights in nonlinear regression analysis of pharmacokinetic data. Drug Metab Rev 1984; 15: 133-148. (Pubitemid 14123934)
17. Peck CC, Beal SL, Sheiner LB, et al. Extended least squares nonlinear regression: a possible solution to the "choice of weights" problem in analysis of individual pharmacokinetic parameters. J Pharmacokinet Biopharm 1984; 12: 545-557.
18. Bjorkman S., Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol 59: 691-704.
19. Bland JM, Altman DG,. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-310. (Pubitemid 16134762)
20. Johnson TN,. Modelling approaches to dose estimation in children. Br J Clin Pharmacol 2005; 59: 663-669. (Pubitemid 40835498)
21. Allonen H, Ziegler G, Klotz U,. Midazolam kinetics. Clin Pharmacol Ther 1981; 30: 653-661.
22. Johnson TN,. The development of drug metabolising enzymes and their influence on the susceptibility to adverse drug reactions in children. Toxicology 2003; 192: 37-48. (Pubitemid 37153342)
23. Johnson TN, Tucker GT, Rostami-Hodjegan A,. Development of CYP2D6 and CYP3A4 in the first year of life. Clin Pharmacol Ther 2008; 83: 670-671. (Pubitemid 351556011)
24. Hines RN, McCarver DG,. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther 2002; 300: 355-360. (Pubitemid 34106223)
25. Lacroix D, Sonnier M, Moncion A, et al. Expression of CYP3A in the human liver-evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 1997; 247: 625-634. (Pubitemid 27308642)
26. Tobin JR,. Paradoxical effects of midazolam in the very young. Anesthesiology 2008; 108: 6-7.
27. de Gast-Bakker DA, van der Werff SD, Sibarani-Ponsen R, et al. Age is of influence on midazolam requirements in a paediatric intensive care unit. Acta Paediatr 2007; 96: 414-417. (Pubitemid 46442532)
28. Persson P, Nilsson A, Hartvig P, et al. Pharmacokinetics of midazolam in total i.v. anaesthesia. Br J Anaesth 1987; 59: 548-556. (Pubitemid 17067929)
29. Nilsson A, Tamsen A, Persson P,. Midazolam-fentanyl anesthesia for major surgery. Plasma levels of midazolam during prolonged total intravenous anesthesia. Acta Anaesthesiol Scand 1986; 30: 66-69. (Pubitemid 16155895)
30. Peeters MY, Prins SA, Knibbe CA, et al. Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery. Anesthesiology 2006; 105: 1135-1146. (Pubitemid 44808577)
31. Mandema JW, Tuk B, van Steveninck AL, et al. Pharmacokinetic- pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 1992; 51: 715-728.
32. Greenblatt DJ, Ehrenberg BL, Gunderman J, et al. Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. Clin Pharmacol Ther 1989; 45: 356-365. (Pubitemid 19126634)
33. Buhrer M, Maitre PO, Crevoisier C, et al. Electroencephalographic effects of benzodiazepines. II. Pharmacodynamic modeling of the electroencephalographic effects of midazolam and diazepam. Clin Pharmacol Ther 1990; 48: 555-567.
34. Johnson TN, Rostami-Hodjegan A, Goddard JM, et al. Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: a pharmacokinetic-pharmacodynamic analysis. Br J Anaesth 2002; 89: 428-437. (Pubitemid 34993972)
35. Kataria BK, Ved SA, Nicodemus HF, et al. The pharmacokinetics of propofol in children using three different data analysis approaches. Anesthesiology 1994; 80: 104-122. (Pubitemid 24033610)
36. Lynn A, Nespeca MK, Bratton SL, et al. Clearance of morphine in postoperative infants during intravenous infusion: the influence of age and surgery. Anesth Analg 1998; 86: 958-963. (Pubitemid 28198858)
37. Peters JW, Anderson BJ, Simons SH, et al. Morphine pharmacokinetics during venoarterial extracorporeal membrane oxygenation in neonates. Intensive Care Med 2005; 31: 257-263. (Pubitemid 40362275)
38. Mathews HM, Carson IW, Lyons SM, et al. A pharmacokinetic study of midazolam in paediatric patients undergoing cardiac surgery. Br J Anaesth 1988; 61: 302-307.
39. Booker PD, Beechey A, Lloyd-Thomas AR,. Sedation of children requiring artificial ventilation using an infusion of midazolam. Br J Anaesth 1986; 58: 1104-1108. (Pubitemid 16031585)
40. Hiller A, Olkkola KT, Isohanni P, et al. Unconsciousness associated with midazolam and erythromycin. Br J Anaesth 1990; 65: 826-828.
41. de Wildt SN, de Hoog M, Vinks AA, et al. Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients. Crit Care Med 2003; 31: 1952-1958. (Pubitemid 36900749)
42. Burtin P, Jacqz-Aigrain E, Girard P, et al. Population pharmacokinetics of midazolam in neonates. Clin Pharmacol Ther 1994; 56: 615-625. (Pubitemid 124006569)
43. de Wildt SN, Kearns GL, Murry DJ, et al. Ontogeny of midazolam glucuronidation in preterm infants. Eur J Clin Pharmacol 2010; 66: 165-170.
44. Blumer J,. Clinical pharmacology of midazolam in infants and children. Clin Pharmacokinet 1998; 35: 37-47. (Pubitemid 28318961)
45. Rhodin MM, Anderson BJ, Peters AM, et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol 2009; 24: 67-76.
46. Blake MJ, Gaedigk A, Pearce RE, et al. Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther 2007; 81: 510-516. (Pubitemid 46452306)
47. Mukherjee A, Dombi T, Wittke B, et al. Population pharmacokinetics of sildenafil in term neonates: evidence of rapid maturation of metabolic clearance in the early postnatal period. Clin Pharmacol Ther 2009; 85: 56-63.
48. Chalkiadis GA, Anderson BJ,. Age and size are the major covariates for prediction of levobupivacaine clearance in children. Pediatr Anesth 2006; 16: 275-282.
49. Egger M, Smith GD, Phillips AN,. Meta-analysis: principles and procedures. BMJ 1997; 315: 1533-1537. (Pubitemid 27517188)
50. Anderson BJ, Merry AF,. Data sharing for pharmacokinetic studies. Paediatr Anaesth 2009; 19: 1005-1010.
51. Lee TC, Charles BG, Harte GJ, et al. Population pharmacokinetic modeling in very premature infants receiving midazolam during mechanical ventilation: midazolam neonatal pharmacokinetics. Anesthesiology 1999; 90: 451-457. (Pubitemid 29071514)
52. Harte GJ, Gray PH, Lee TC, et al. Haemodynamic responses and population pharmacokinetics of midazolam following administration to ventilated, preterm neonates. J Paediatr Child Health 1997; 33: 335-338. (Pubitemid 27396189)
53. de Wildt SN, Kearns GL, Hop WC, et al. Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. Clin Pharmacol Ther 2001; 70: 525-531. (Pubitemid 34008409)
54. Jacqz-Aigrain E, Daoud P, Burtin P, et al. Pharmacokinetics of midazolam during continuous infusion in critically ill neonates. Eur J Clin Pharmacol 1992; 42: 329-332.
55. Jacqz-Aigrain E, Wood C, Robieux I,. Pharmacokinetics of midazolam in critically ill neonates. Eur J Clin Pharmacol 1990; 39: 191-192. (Pubitemid 20249998)
56. Mulla H, McCormack P, Lawson G, et al. Pharmacokinetics of midazolam in neonates undergoing extracorporeal membrane oxygenation. Anesthesiology 2003; 99: 275-282. (Pubitemid 36909552)
57. Muchohi SN, Kokwaro GO, Ogutu BR, et al. Pharmacokinetics and clinical efficacy of midazolam in children with severe malaria and convulsions. Br J Clin Pharmacol 2008; 66: 529-538.
58. Rey E, Delaunay L, Pons G, et al. Pharmacokinetics of midazolam in children: comparative study of intranasal and intravenous administration. Eur J Clin Pharmacol 1991; 41: 355-357.
59. Payne K, Mattheyse FJ, Liebenberg D, et al. The pharmacokinetics of midazolam in paediatric patients. Eur J Clin Pharmacol 1989; 37: 267-272. (Pubitemid 19242733)
60. Salonen M, Kanto J, Iisalo E, et al. Midazolam as an induction agent in children: a pharmacokinetic and clinical study. Anesth Analg 1987; 66: 625-628. (Pubitemid 17113612)
61. Tolia V, Brennan S, Aravind MK, et al. Pharmacokinetic and pharmacodynamic study of midazolam in children during esophagogastroduodenoscopy. J Pediatr 1991; 119: 467-471.
62. Hughes J, Gill AM, Mulhearn H, et al. Steady-state plasma concentrations of midazolam in critically ill infants and children. Ann Pharmacother 1996; 30: 27-30. (Pubitemid 26025415)
63. Clausen TG, Wolff J, Hansen PB, et al. Pharmacokinetics of midazolam and alpha-hydroxy-midazolam following rectal and intravenous administration. Br J Clin Pharmacol 1988; 25: 457-463.
64. Pentikainen PJ, Valisalmi L, Himberg JJ, et al. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J Clin Pharmacol 1989; 29: 272-277. (Pubitemid 19087927)
65. Albrecht S, Ihmsen H, Hering W, et al. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. Clin Pharmacol Ther 1999; 65: 630-639. (Pubitemid 29294026)
66. Bjorkman S, Wada DR, Berling BM,. Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model. J Pharm Sci 2001; 90: 1226-1241. (Pubitemid 32867972)
67. Greenblatt DJ, Abernethy DR, Locniskar A, et al. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 1984; 61: 27-35. (Pubitemid 14089351)
68. Bjorkman S, Rigemar G, Idvall J, Pharmacokinetics of midazolam given as an intranasal spray to adult surgical patients. 1997; 79: 575-580.